Therapeutics News and Research

RSS

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Yaupon Therapeutics, Inc., a privately held specialty pharmaceutical company, announced today the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its propriety gel formulation of mechlorethamine hydrochloride (mechlorethamine).

28 Jul 2011

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

Safeguard Scientifics, Inc., a holding company that builds value in growth-stage life sciences and technology companies, today announced results of operations for the second quarter of 2011.

27 Jul 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data published in the online edition of Circulation Research suggests that microRNA-15 (miR-15) inhibits cardiomyogenesis, the process whereby new heart muscle cells are formed.

27 Jul 2011

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, together with collaborators at the Massachusetts Institute of Technology (MIT), announced today the publication of new paper describing discovery of "core-shell" nanoparticles for systemic delivery of RNAi therapeutics.

26 Jul 2011

PharmaNet to assist BrainStorm in obtaining FDA approval for ALS human clinical trials

BrainStorm Cell Therapeutics Inc., an innovative developer of adult stem cell technologies and CNS therapeutics, announced today that it has signed an agreement with PharmaNet LLC, an inVentiv Health Company, to assist in the development of the protocol and IND file for submission to the FDA for approval of BrainStorm's ALS human clinical trials in the United States.

26 Jul 2011

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

The Resolute drug-eluting stent (DES) from Medtronic, Inc., showed superiority to Boston Scientific Corp.'s Taxus DES on the primary endpoint of the RESOLUTE Japan clinical study: in-stent late lumen loss at eight months.

26 Jul 2011

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

Biogen Idec announced today it has received conditional approval from the European Commission for FAMPYRA® (prolonged-release fampridine tablets) to improve walking in adult patients with multiple sclerosis who have walking disability.

25 Jul 2011

New method for detecting breast cancer at 'stage 0'

RNL Natural Co., Ltd, a leading biotech company specialized in adult stem cell therapeutics affiliated with RNL BIO Co., Ltd., introduced on June 22, 2011 a new method of detecting breast cancer as early as at 'stage 0' through breath VOCs.

25 Jul 2011

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Sangamo BioSciences, Inc. announced the publication of a study demonstrating the use of zinc finger nucleases (ZFNs) to produce genetically modified pigs. The study, which was published in the Proceedings of the National Academy of Sciences (PNAS), represents a significant advancement in the development of improved, less immunogenic animal tissue as a source for transplant into humans.

22 Jul 2011

Combination of strategies reduces more than half the number of tiger mosquitos

The combination of three complementary measures to eradicate tiger mosquitos - avoid having stagnant water, using insecticides to eliminate larvae and adults, and removing rubbish - reduces more than half the number of tiger mosquitos, according to a research coordinated by researchers at Universitat Autonoma de Barcelona.

22 Jul 2011

A*STAR's ETC, Agilent introduce drug screening platform

Agilent Technologies Inc. and A*STAR's Experimental Therapeutics Centre (ETC) today announced the launch of a drug screening platform within ETC's new Singapore Screening Centre.

22 Jul 2011

Scripps Research, Jupiter Medical Center partner for cancer study

In a first for both institutions, Jupiter Medical Center, the area's Number One Preferred Hospital, and The Scripps Research Institute, one of the world's largest private, non-profit biomedical research organizations, are teaming up to conduct research on human cancer tissue.

22 Jul 2011

Australian anti-cancer company completes $2.6 million placement

Australian monoclonal antibody company, Immune System Therapeutics Limited (IST), today said it completed a private placement to raise $2 million from new and existing private and institutional investors in Australia. Investors have agreed to purchase 5,200,000 shares in the company at a price of $0.50 cents per share resulting in gross proceeds of $2.6 million.

21 Jul 2011

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Galectin Therapeutics Inc. today announced that it has entered into a research collaboration with Dr. Jose Jalife of the University of Michigan Medical School to better understand the relationship of Galectin-3 to cardiac fibrosis in chronic cardiac arrhythmias.

21 Jul 2011

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has identified a third microRNA target in its alliance with GlaxoSmithKline (GSK), triggering a preclinical milestone payment from GSK.

21 Jul 2011

Baxter net income increases 15% to $615 million for second quarter 2011

Baxter International Inc. today announced strong financial results for the second quarter of 2011, and raised its financial outlook for full-year 2011.

From Baxter International Inc. 21 Jul 2011

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Children and adults with social withdrawal due to Fragile X syndrome, the most common cause of inherited intellectual disability and the most common known single gene cause of autism, may benefit from an experimental drug under study by pediatric neurologists at Rush Children's Hospital at Rush University Medical Center.

21 Jul 2011

Therapeutics News and Research

Yaupon seeks FDA marketing approval of mechlorethamine gel for mycosis fungoides

Safeguard Scientifics reports consolidated net income of $121.8M for second quarter 2011

New preclinical data suggests microRNA-15 inhibits cardiomyogenesis

'Core-shell' nanoparticles for effective intracellular delivery of RNAi therapeutics

PharmaNet to assist BrainStorm in obtaining FDA approval for ALS human clinical trials

Resolute drug-eluting stent superior to Taxus DES for coronary artery disease

Biogen Idec's FAMPYRA receives EU conditional approval for treating functional impairment in MS

New method for detecting breast cancer at 'stage 0'

Advancements in use of zinc finger nucleases to produce genetically modified pigs

Combination of strategies reduces more than half the number of tiger mosquitos

A*STAR's ETC, Agilent introduce drug screening platform

Scripps Research, Jupiter Medical Center partner for cancer study

Australian anti-cancer company completes $2.6 million placement

Galectin, University of Michigan enter collaboration to study role of Galectins in cardiovascular disease

Identification of third microRNA target triggers milestone payment from GSK to Regulus

Baxter net income increases 15% to $615 million for second quarter 2011

Children and adults with social withdrawal due to Fragile X may benefit from STX209

Promising compounds for new anti-obesity drugs

Researchers identify IDOL protein as potential new target for lowering LDL cholesterol

AMAG enters definitive merger agreement with Allos Therapeutics

Industry Focus eBook - Cell biology (5th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News